Minovia

What Minovia does

Minovia Therapeutics Ltd. is an Israel-based, clinical-stage biotechnology company (founded circa 2015, headquartered in Tirat Carmel) pioneering a Mitochondrial Augmentation Technology (MAT) platform, which transplants healthy, functional mitochondria into patients with mitochondrial dysfunction. The company describes itself as the first clinical-stage firm to use mitochondrial transplantation, targeting the root cause of mitochondrial diseases rather than symptomatic treatment. Its pipeline centers on lead candidate MNV-201 for low-risk myelodysplastic syndrome (MDS), which has demonstrated a high safety profile and clinical benefits in a Phase 1b trial and has received FDA Orphan Drug, Fast Track, and Rare Pediatric Disease Designations. Complementary assets include proprietary mitochondrial biomarker assays intended to measure mitochondrial health and support diagnostic tool development.

The company's intended customer base spans three patient populations: children and adults with rare mitochondrial diseases caused by nuclear or mtDNA mutations and deletions; low-risk MDS patients; and patients with age-related diseases linked to mitochondrial dysfunction and aging. Scientific and clinical validation is communicated through peer channels such as the American Society of Hematology (ASH) Annual Meeting, and the company engages patient advocacy groups to inform development plans.

Minovia is pre-revenue and clinical-stage, with funding to date drawn primarily from a $350,000 grant awarded in August 2025 by Countdown For A Cure for mitochondrial biomarker research. There are no disclosed product sales, licensing income, or institutional venture capital rounds. In June 2025, Minovia announced a proposed business combination with SPAC Launch One Acquisition Corp. to list on Nasdaq, with closing targeted for Q4 2025 and an explicit pivot toward the $1 trillion+ mitochondrial and longevity market opportunity. The company is founder-led by Natalie Yivgi-Ohana, PhD, with a small leadership team (11–50 employees total) including a designated CMO and Executive Chairman.

Name

Minovia

Legal name

Minovia Therapeutics Ltd.

Website

https://minovia.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Minovia Therapeutics is an Israeli clinical-stage biotech pioneering Mitochondrial Augmentation Technology (MAT), with lead candidate MNV-201 in Phase 1b trials for myelodysplastic syndrome, targeting patients with rare mitochondrial diseases and age-related mitochondrial dysfunction.

Ownership category

akta.pro rank

Product category

Mitochondrial Therapeutics

NAICS

Scientific Research and Development Services (5417)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)

akta.pro secondary industry

Neurology/CNS Gene Therapies (HLAAACAH)

Keywords

• Mitochondrial therapy
• Cell therapy platform
• Clinical-stage biotechnology
• Mitochondrial transplantation
• Rare disease therapeutics

Headquarters

HQ city

Tirat Carmel

HQ country

Israel

HQ region

Middle East

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Mitochondrial Therapies Pipeline: Pre-revenue clinical stage company developing therapeutic pipeline targeting mitochondrial dysfunction and age-related diseases. Revenue expected upon regulatory approval and commercialization of lead product candidates including MNV-201 for MDS.

Marketing channels4 records

Core offering

Minovia Therapeutics develops mitochondria-based therapies using its Mitochondrial Augmentation Technology (MAT) platform, which transplants healthy, functional mitochondria into patients with mitochondrial dysfunction. Its lead product candidate, MNV-201, is in clinical development for myelodysplastic syndrome (MDS) and has received FDA Orphan Drug, Fast Track, and Rare Pediatric Disease Designations. The company also develops proprietary biomarker assays to measure mitochondrial health for diagnostic and therapeutic monitoring applications.

Product overview

Minovia Therapeutics is the first clinical stage company using mitochondrial transplantation approach. The company operates with a unified Mitochondrial Augmentation Technology (MAT) platform comprising three interconnected offerings: (1) MNV-201, the lead clinical-stage therapy product for myelodysplastic syndrome (MDS) that demonstrated high safety and clinical benefits in Phase 1b trials and has received FDA Orphan Drug Designation; (2) the MAT platform technology itself enabling transplantation of healthy mitochondria for treating mitochondrial diseases; and (3) proprietary mitochondrial biomarker assays for measuring mitochondrial health and supporting diagnostic development. The platform spans from rare diseases to age-related conditions.

Differentiator

Problem solved

Functional benefit

Brands

• MNV-201: Lead product - investigational mitochondrial augmentation therapy for myelodysplastic syndrome (MDS) demonstrating high safety profile and clinical benefits in Phase 1b trial

Products and services

• MNV-201 Lead product candidate based on Minovia's Mitochondrial Augmentation Technology (MAT) for the treatment of myelodysplastic syndrome (MDS), demonstrated in a Phase 1b trial to have a high safety profile and clinical benefits in low-risk MDS patients.
• Mitochondrial Biomarker Assays Proprietary analytical assays and biomarkers intended to measure mitochondrial health, supporting development of diagnostic tools and treatments for mitochondrial dysfunction associated with various diseases and aging.

Quantifiable outcome

• Phase 1b trial demonstrated high safety profile and clinical benefits for MNV-201 in low-risk MDS patients
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Children's Hospital of Philadelphia (CHOP)coreStrategic or Co-development Partner · 7 February 2026Dr. Douglas C. Wallace, Director of the Center for Mitochondrial & Epigenomic Medicine at CHOP, was honored at CFAC's gala where Minovia's work on mitochondrial biomarker development was featured. CHOP represents a key research institution in mitochondrial medicine.
• ASH (American Society of Hematology)minorStrategic or Co-development PartnerMinovia presented data on its mitochondrial augmentation technology at the 67th ASH Annual Meeting and Exposition in Orlando, FL. The presentation included pre-clinical and Phase 1b clinical trial results for MNV-201 in MDS treatment.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Stealth BioTherapeutics: Clinical-stage biotech developing mitochondria-targeted therapies (e.g., elamipretide) for rare mitochondrial diseases. Most directly comparable to Minovia in mechanism and indication focus.
• Khondrion: Clinical-stage biopharmaceutical company developing small-molecule therapies for mitochondrial diseases including MELAS and Leigh syndrome. Directly comparable as a mitochondrial-disease-focused clinical biotech.
• Reneo Pharmaceuticals: Clinical-stage biotech developing therapies for rare mitochondrial myopathies and related metabolic disorders. Closely comparable in rare mitochondrial indication targeting.
• Abliva (formerly NeuroVive Pharmaceutical Asia): Swedish clinical-stage biotech developing treatments for primary mitochondrial disease (e.g., KL1333 for MELAS). Direct mitochondrial-disease therapeutic peer.

Broad incumbents

• bluebird bio: Cell and gene therapy company focused on severe genetic diseases including mitochondrial-related disorders. Comparable as a clinical-stage cell/gene therapy developer in rare diseases, though broader in scope than Minovia's mitochondrial focus.
• PTC Therapeutics: Established rare-disease biopharma with multiple mitochondrial-disease programs (e.g., vatiquinone for Friedreich's ataxia, Emflaza). Comparable as a larger rare-disease player intersecting with mitochondrial medicine.
• Zogenix (now part of UCB): Rare-disease focused biopharma with mitochondrial-disease assets (e.g., MT1621 for TK2 deficiency). Comparable as a larger rare-disease peer with overlapping mitochondrial therapeutic interests.
• Bristol-Myers Squibb (Reblozyl / Acceleron franchise): BMS markets Reblozyl (luspatercept) for MDS via the Acceleron acquisition, making it the most relevant established MDS competitor and a benchmark for MNV-201's commercial landscape.

Emerging players

• uniQure: Clinical-stage gene therapy company developing AAV-based treatments for rare diseases. Comparable as a gene therapy developer targeting rare monogenic indications, with a similar clinical-stage profile.
• Rocket Pharmaceuticals: Clinical-stage gene therapy company developing AAV-based treatments for rare pediatric diseases. Comparable as a cell/gene therapy developer targeting rare monogenic indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/minoviatherapeutics
• Xx.com/MinoviaTx

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Minovia